306 related articles for article (PubMed ID: 28942098)
41. Axillary staging in breast cancer patients treated with neoadjuvant chemotherapy in two Dutch phase III studies.
Vriens BEPJ; Keymeulen KBMI; Kroep JR; Charehbili A; Peer PG; de Boer M; Aarts MJB; Heuts EM; Tjan-Heijnen VCG;
Oncotarget; 2017 Jul; 8(28):46557-46564. PubMed ID: 28177921
[TBL] [Abstract][Full Text] [Related]
42. Treatment options for locally advanced breast cancer--experience in an Asian tertiary hospital.
Chong HY; Taib NA; Rampal S; Saad M; Bustam AZ; Yip CH
Asian Pac J Cancer Prev; 2010; 11(4):913-7. PubMed ID: 21133600
[TBL] [Abstract][Full Text] [Related]
43. Muscle mass loss after neoadjuvant chemotherapy in breast cancer: estimation on breast magnetic resonance imaging using pectoralis muscle area.
Rossi F; Torri L; Lambertini M; De Giorgis S; Calabrese M; Tagliafico AS
Eur Radiol; 2020 Aug; 30(8):4234-4241. PubMed ID: 32232787
[TBL] [Abstract][Full Text] [Related]
44. Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses.
Yang Y; Im SA; Keam B; Lee KH; Kim TY; Suh KJ; Ryu HS; Moon HG; Han SW; Oh DY; Han W; Kim TY; Park IA; Noh DY
BMC Cancer; 2016 Jul; 16():515. PubMed ID: 27444430
[TBL] [Abstract][Full Text] [Related]
45. Are there changes in characteristics and therapy of young patients with early-onset breast cancer in Germany over the last decade?
Banz-Jansen C; Heinrichs A; Hedderich M; Waldmann A; Wedel B; Mebes I; Diedrich K; Rody A; Fischer D
Arch Gynecol Obstet; 2013 Aug; 288(2):379-83. PubMed ID: 23407999
[TBL] [Abstract][Full Text] [Related]
46. Differences in Response and Surgical Management with Neoadjuvant Chemotherapy in Invasive Lobular Versus Ductal Breast Cancer.
Truin W; Vugts G; Roumen RM; Maaskant-Braat AJ; Nieuwenhuijzen GA; van der Heiden-van der Loo M; Tjan-Heijnen VC; Voogd AC
Ann Surg Oncol; 2016 Jan; 23(1):51-7. PubMed ID: 25980321
[TBL] [Abstract][Full Text] [Related]
47. Serial MRI scans help in assessing early response to neoadjuvant chemotherapy and tailoring breast cancer treatment.
Fatayer H; Sharma N; Manuel D; Kim B; Keding A; Perren T; Velikova G; Lansdown M; Shaaban AM; Dall B
Eur J Surg Oncol; 2016 Jul; 42(7):965-72. PubMed ID: 27260848
[TBL] [Abstract][Full Text] [Related]
48. Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy.
Keam B; Im SA; Kim HJ; Oh DY; Kim JH; Lee SH; Chie EK; Han W; Kim DW; Cho N; Moon WK; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
Breast Cancer Res Treat; 2009 Jul; 116(1):153-60. PubMed ID: 18787948
[TBL] [Abstract][Full Text] [Related]
49. Compliance differences between patients with breast cancer in university and county hospitals.
Komenaka IK; Pennington RE; Schneider BP; Hsu CH; Norton LE; Clare SE; Zork NM; Goulet RJ
Clin Breast Cancer; 2010 Oct; 10(5):385-91. PubMed ID: 20920983
[TBL] [Abstract][Full Text] [Related]
50. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH
Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072
[TBL] [Abstract][Full Text] [Related]
51. Alterations of biomarker profiles after neoadjuvant chemotherapy in breast cancer: tumor heterogeneity should be taken into consideration.
Zhou X; Zhang J; Yun H; Shi R; Wang Y; Wang W; Lagercrantz SB; Mu K
Oncotarget; 2015 Nov; 6(34):36894-902. PubMed ID: 26384297
[TBL] [Abstract][Full Text] [Related]
52. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer.
Ono M; Tsuda H; Shimizu C; Yamamoto S; Shibata T; Yamamoto H; Hirata T; Yonemori K; Ando M; Tamura K; Katsumata N; Kinoshita T; Takiguchi Y; Tanzawa H; Fujiwara Y
Breast Cancer Res Treat; 2012 Apr; 132(3):793-805. PubMed ID: 21562709
[TBL] [Abstract][Full Text] [Related]
53. Impact of biomarker changes during neoadjuvant chemotherapy for clinical response in patients with residual breast cancers.
Enomoto Y; Morimoto T; Nishimukai A; Higuchi T; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Nomura T; Takeda M; Watanabe T; Hirota S; Miyoshi Y
Int J Clin Oncol; 2016 Apr; 21(2):254-261. PubMed ID: 26338270
[TBL] [Abstract][Full Text] [Related]
54. [Analysis of the factors affecting pathologic complete response to neoadjuvant chemotherapy in breast cancer patients].
Sun B; Song ST; Jiang ZF; Wang T; Zhang SH; Meng XY; Li XB; Yu CZ; Wu SK
Zhonghua Zhong Liu Za Zhi; 2013 Jan; 35(1):38-42. PubMed ID: 23648298
[TBL] [Abstract][Full Text] [Related]
55. Hospital organizational factors affect the use of immediate breast reconstruction after mastectomy for breast cancer in the Netherlands.
Schreuder K; van Bommel ACM; de Ligt KM; Maduro JH; Vrancken Peeters MTFD; Mureau MAM; Siesling S
Breast; 2017 Aug; 34():96-102. PubMed ID: 28552797
[TBL] [Abstract][Full Text] [Related]
56. Is regional lymph node irradiation necessary in stage II to III breast cancer patients with negative pathologic node status after neoadjuvant chemotherapy?
Daveau C; Stevens D; Brain E; Berges O; Villette S; Moisson P; Gardner M; De la Lande B; Lasry S; Labib A; Le Scodan R
Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):337-42. PubMed ID: 20171795
[TBL] [Abstract][Full Text] [Related]
57. Perioperative treatment and radical cystectomy for bladder cancer--a population based trend analysis of 10,338 patients in the Netherlands.
Hermans TJN; Fransen van de Putte EE; Horenblas S; Lemmens V; Aben K; van der Heijden MS; Beerepoot LV; Verhoeven RH; van Rhijn BWG
Eur J Cancer; 2016 Feb; 54():18-26. PubMed ID: 26707593
[TBL] [Abstract][Full Text] [Related]
58. Ultrasound is at least as good as magnetic resonance imaging in predicting tumour size post-neoadjuvant chemotherapy in breast cancer.
Vriens BE; de Vries B; Lobbes MB; van Gastel SM; van den Berkmortel FW; Smilde TJ; van Warmerdam LJ; de Boer M; van Spronsen DJ; Smidt ML; Peer PG; Aarts MJ; Tjan-Heijnen VC;
Eur J Cancer; 2016 Jan; 52():67-76. PubMed ID: 26650831
[TBL] [Abstract][Full Text] [Related]
59. Breast cancer biomarkers before and after neoadjuvant chemotherapy: does repeat testing impact therapeutic management?
Xian Z; Quinones AK; Tozbikian G; Zynger DL
Hum Pathol; 2017 Apr; 62():215-221. PubMed ID: 28041972
[TBL] [Abstract][Full Text] [Related]
60. [Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer. Its relation with molecular subtypes].
Ruano R; Ramos M; García-Talavera JR; Ramos T; Rosero AS; González-Orus JM; Sancho M
Rev Esp Med Nucl Imagen Mol; 2014; 33(6):340-5. PubMed ID: 24856234
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
